Ipsen Completes Acquisition of French Biotech Firm ImCheck Therapeutics
The French pharmaceutical group announced this Sunday that it has completed the acquisition of ImCheck Therapeutics, a private French company specializing in immuno-oncology therapies.
Completion of Acquisition
Ipsen has finalized the acquisition of ImCheck Therapeutics on December 15, 2025, according to a statement released this Sunday. The acquired company is described by the group as a private French biotechnology company specializing in the development of next-generation immuno-oncology therapies. This operation aims to strengthen the French laboratory's oncology portfolio, one of its three priority therapeutic areas alongside rare diseases and neuroscience. However, the statement does not specify the amount of the transaction or the financial terms of the acquisition.
Company Profile
According to the group, Ipsen defines itself as a global biopharmaceutical laboratory focused on three main therapeutic areas: oncology, rare diseases, and neuroscience. The statement recalls that the company has nearly 100 years of experience in drug development, with research centers located in the United States, France, and the United Kingdom. The group indicates that it is present in over 40 countries and markets its products in more than 100 countries worldwide. Ipsen states that its research and development product portfolio relies on both internal innovation and external acquisitions.
Stock Market Presence
According to information provided in the statement, Ipsen is listed on the Euronext market in Paris under the symbol IPN. The group also has a Level I American Depositary Receipt program in the United States, listed under the symbol IPSEY. This dual listing allows the laboratory to be accessible to both European and American investors. The statement does not include any information on the potential impact of this acquisition on the group's financial results or its short- or medium-term outlook.
